Intravacc B.V.
http://www.intravacc.nl/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Intravacc B.V.
Tech Transfer Roundup: Boehringer Teams Up With A*STAR On Targeted Oncology R&D
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
The Year in Deals: Hold That Acquisition!
After several years of intense consolidation, many medical products companies--the healthier ones, at least--seem to be taking a breather. Drug mergers are way down, while medical devices has become a buyer's market. And biotech consolidation isn't likely anytime soon. Only in slow-growing diagnostics is consolidation the rage.
The Glaxo/SmithKline Debacle: Unanswered Questions
The proposed merger of SmithKline Beecham and Glaxo Wellcome PLC sent waves of anxiety when it was announced--and relief when it was canceled. The deal ran aground because of disagreements over who would run the company. But the larger questions it raised--about the need for greater critical mass in R&D and the likelihood of future mergers--won't go away so easily.
Company Information
- Industry
- Academic and Research Institutions
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice